Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Visentin

Showing results (81-90 of 193) with videos related to

Pageof 20
Sort By:
Current Oncology (Toronto, Ont.)|January 20, 2023
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody DeficiencyAndrea Visentin, Maria Chiara Molinari, Stefano Pravato, et al.
British Journal of Haematology|May 6, 2024
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimensAndrea Serafin, Alessandro Cellini, Chiara Adele Cavarretta, et al.
Frontiers in Oncology|January 29, 2026
Prognostic and predictive impact of NOTCH1 mutations in patients with chronic lymphocytic leukemia: a tertiary single-center experienceMattia D'Antiga, Andrea Serafin, Francesco Angotzi, et al.
Hematological Oncology|September 26, 2020
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literatureAndrea Visentin, Silvia Imbergamo, Valentina Trimarco, et al.
British Journal of Haematology|July 27, 2020
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemiaAndrea Corbingi, Idanna Innocenti, Annamaria Tomasso, et al.
Plos One|March 4, 2021
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficienciesFrancesco Cinetto, Raffaella Neri, Fabrizio Vianello, et al.
Blood|November 12, 2020
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironmentLaura Patrussi, Noemi Manganaro, Nagaja Capitani, et al.
BMC Medicine|June 30, 2026
Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemiaMaria Castronuovo, Guido Capasso, Allison Beltrame, et al.
British Journal of Haematology|July 6, 2018
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndromeAndrea Visentin, Silvia Imbergamo, Edoardo Scomazzon, et al.
International Journal of Cancer|May 3, 2019
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemiaFederica Frezzato, Flavia Raggi, Veronica Martini, et al.
Pageof 20

Showing results (81-90 of 193) with videos related to

Sort By:
Pageof 20
Current Oncology (Toronto, Ont.)|January 20, 2023
A Retrospective Study on the Efficacy of Subcutaneous Immunoglobulin as Compared to Intravenous Formulation in Patients with Chronic Lymphocytic Leukemia and Secondary Antibody DeficiencyAndrea Visentin, Maria Chiara Molinari, Stefano Pravato, et al.
British Journal of Haematology|May 6, 2024
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimensAndrea Serafin, Alessandro Cellini, Chiara Adele Cavarretta, et al.
Frontiers in Oncology|January 29, 2026
Prognostic and predictive impact of NOTCH1 mutations in patients with chronic lymphocytic leukemia: a tertiary single-center experienceMattia D'Antiga, Andrea Serafin, Francesco Angotzi, et al.
Hematological Oncology|September 26, 2020
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literatureAndrea Visentin, Silvia Imbergamo, Valentina Trimarco, et al.
British Journal of Haematology|July 27, 2020
Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemiaAndrea Corbingi, Idanna Innocenti, Annamaria Tomasso, et al.
Plos One|March 4, 2021
Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficienciesFrancesco Cinetto, Raffaella Neri, Fabrizio Vianello, et al.
Blood|November 12, 2020
Enhanced IL-9 secretion by p66Shc-deficient CLL cells modulates the chemokine landscape of the stromal microenvironmentLaura Patrussi, Noemi Manganaro, Nagaja Capitani, et al.
BMC Medicine|June 30, 2026
Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemiaMaria Castronuovo, Guido Capasso, Allison Beltrame, et al.
British Journal of Haematology|July 6, 2018
BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndromeAndrea Visentin, Silvia Imbergamo, Edoardo Scomazzon, et al.
International Journal of Cancer|May 3, 2019
HSP70/HSF1 axis, regulated via a PI3K/AKT pathway, is a druggable target in chronic lymphocytic leukemiaFederica Frezzato, Flavia Raggi, Veronica Martini, et al.
Pageof 20